Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

v3.3.1.900
Subsequent Events - Additional Information (Detail)
1 Months Ended 12 Months Ended
Apr. 24, 2015
USD ($)
Feb. 29, 2016
USD ($)
Employee
Dec. 31, 2015
USD ($)
shares
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Reduction in workforce | Employee   11  
Percentage of workforce reduction   27.00%  
Cash expenditures on workforce reduction   $ 400,000  
Chief Executive Officer      
Subsequent Event [Line Items]      
Consulting services paid     $ 500,000
Stock options granted to purchase | shares     37,500
Restricted stock units granted | shares     18,750
Accounts payable, related parties     $ 400,000
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member]      
Subsequent Event [Line Items]      
Lawsuit filing date     January 5, 2016
Proceeds from advance reimbursement research and development, net amount $ 23,200,000    
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member] | Maximum [Member]      
Subsequent Event [Line Items]      
Damages arise due to termination of agreement     $ 10,000,000